KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Karyopharm Therapeutics Inc.

85 Wells Avenue
2nd Floor
Newton, MA 02459
United States
617-658-0600
http://www.karyopharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees332

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael G. KauffmanCo-Founder, CEO & Director830.28k1.48M1963
Dr. Sharon ShachamCo-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board644.72k2.01M1970
Mr. Christopher Brett PrimianoExec. VP, Chief Bus. Officer, Gen. Counsel & Sec.619.68k108.45k1981
Dr. Mansoor Raza MirzaClinical Consultant, Member of Scientific Advisory Board & Director152kN/A1961
Mr. Michael P. MasonSr. VP, CFO & TreasurerN/AN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency. The company also reported positive results from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. Selinexor is also being evaluated in various other mid-and later-phase clinical trials in various cancer indications, including in multiple myeloma in a randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), as well as a therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL), in recurrent gliomas (KING), in endometrial cancer (SIENDO), and others. The company's SINE compounds also have biological activity in various models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. In addition, it has various investigational programs in clinical or preclinical development. The company was founded in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.